Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Post-traumatic Headache
NCT06839118Phase 3Recruiting
- Sponsor
- Dansk Hovedpinecenter
- Start
- Jan 2025
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-traumatic headache (PTH) comparing BTX-A with Placebo (2 arms). Primary endpoint: Change in the number of moderate-to-severe headache days. Started Jan 2025; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
post-traumatic headache (PTH)
Beyond the preview
Go deeper on NCT06839118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06839118.